
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) has received mixed reviews from various experts, highlighting both its strengths and concerns. Many praise the company for its solid performance in Asia and wealth management, coupled with a healthy dividend yield, making it an attractive income stock. However, some analysts express caution due to overvaluation, suggesting that MFC may be overbought, trading at over 2x book value with slow earnings growth of around 8-9%. While the stock is seen as a reasonable long-term holding, there are calls for potential buying opportunities during market pullbacks. The general sentiment reflects a wait-and-see approach given the mixed indicators and the overall health of the financial sector.
A core holding. Shares haven't done much over the past two years. Rising interest rates will kick some life into insurance stocks. MFC needs to sort out its John Hancock division in the U.S. Its Asian franchise is the crown jewel, though, so as this franchise grows, so will this stock. MFC has a strong presence in Asia where insurance is not saturated like it is in North America.
Responding to a caller who argued that the company’s financials are strong and asked why it is not selling for $30. Steinberg responded that it is a mistake to evaluate this company on its own. Globally, the financial services sector is under pressure. Global banks are under pressure. European insurers are trading at single-digit multiples. For a value investor, these are opportunities to step into good companies at fairly low earnings multiples. Manulife is well-run, has a healthy level of international business, and pays a good dividend. He expects dividend growth. Rather than being frustrated with companies like this, value investors step in and buy them.
It's gone nowhere in the last year, but up 25% in the past five. Earnings growth is good. New management's focus is on wealth management and Asia. Yes, John Hancock is a legacy they continue to deal with, but MFC's operational side is doing fairly well and its Asian operations are gangbusters, showing impressive growth.
He likes trading sideways stocks, as long as you know the downside potential. He recently bought MFC off the mid-$20's bounce, and he believes it could teach the mid-high-$20's. Not a huge trade, but pays a good dividend. It could reach that peak in the winter. And it's not a high-risk play. (3.7% dividend, Analysts' price target: $30.03)
He owned it going into the financial crisis and bailed out because it was overleveraged to markets and was unhedged. After it was hurt by this, it overreacted and is now so well hedged that it cannot benefit from rising interest rates. He likes the life insurance industry and owns three companies in that space, but not this one. Among Canadian insurers, he prefers Sun Life. He thinks it is better managed, with better exposure to interest rates. He likes the international diversification of both Manulife and Sun Life, but Manulife’s biggest international diversification is via John Hancock in the US, which is troubled.
This is one of the few Canadian companies he owns. He likes it. He likes the potential of the business, and the leverage to higher rates. The stock rose in expectation of higher rates and dropped off when the main increases were postponed. The company struggled with its US business, but now the company is stronger, the dividend is fine and will gradually increase. Eventually the Asian expansion will pay off and the stock will probably move to the low $30’s, which is where many people have set a target price. He would nibble away at it at this price. He would buy a lot more at $20 and would sell some at $32.
(A Top Pick October 23, 2017. Down 6%) All insurers are suffering from the yield curve (the low difference between short-term and long-term rates). The worst is over for the entire sector. Manulife should have 10% earnings growth over the next 10 years even with the current environment. He likes the insurance sector generally and he likes the US and Asian exposure of Manulife.